Aimmune Therapeutics, Inc. (NASDAQ:AIMT) had its price objective increased by analysts at Credit Suisse Group from $36.00 to $45.00 in a note issued to investors on Monday, MarketBeat Ratings reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Credit Suisse Group’s price target would indicate a potential upside of 33.99% from the stock’s previous close.

A number of other brokerages have also commented on AIMT. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Wedbush reaffirmed an “outperform” rating and set a $70.00 target price (up previously from $42.00) on shares of Aimmune Therapeutics in a report on Monday. Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Saturday. Finally, BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Aimmune Therapeutics presently has an average rating of “Hold” and an average target price of $51.00.

Aimmune Therapeutics (AIMT) traded up 36.13% during mid-day trading on Monday, hitting $34.93. 6,986,087 shares of the company’s stock were exchanged. Aimmune Therapeutics has a 12 month low of $14.87 and a 12 month high of $37.50. The stock’s market cap is $1.77 billion. The stock’s 50 day moving average price is $24.75 and its 200-day moving average price is $24.75.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). Equities analysts expect that Aimmune Therapeutics will post ($2.71) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Aimmune Therapeutics, Inc. (AIMT) PT Raised to $45.00 at Credit Suisse Group” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/23/aimmune-therapeutics-inc-aimt-receives-outperform-rating-from-credit-suisse-group.html.

In other news, CEO Stephen George Dilly sold 1,154 shares of the firm’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $26.24, for a total value of $30,280.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Susan E. Barrowcliffe sold 6,110 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $22.00, for a total transaction of $134,420.00. Following the completion of the sale, the insider now directly owns 960 shares of the company’s stock, valued at $21,120. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 325,000 shares of company stock valued at $7,922,482. Corporate insiders own 24.56% of the company’s stock.

Several large investors have recently bought and sold shares of AIMT. Vanguard Group Inc. lifted its position in shares of Aimmune Therapeutics by 30.5% in the 1st quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock worth $47,803,000 after purchasing an additional 513,803 shares during the period. State Street Corp lifted its position in shares of Aimmune Therapeutics by 49.1% in the 1st quarter. State Street Corp now owns 858,891 shares of the biotechnology company’s stock worth $18,663,000 after purchasing an additional 282,744 shares during the period. Point72 Asset Management L.P. lifted its position in shares of Aimmune Therapeutics by 67.3% in the 1st quarter. Point72 Asset Management L.P. now owns 681,973 shares of the biotechnology company’s stock worth $14,819,000 after purchasing an additional 274,273 shares during the period. Eagle Asset Management Inc. lifted its position in shares of Aimmune Therapeutics by 6.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,270,160 shares of the biotechnology company’s stock worth $46,674,000 after purchasing an additional 135,374 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in shares of Aimmune Therapeutics by 139.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock worth $4,675,000 after purchasing an additional 132,603 shares during the period. 72.90% of the stock is owned by hedge funds and other institutional investors.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.